Complianz World is a US based company, and a leading GRC training provider has announced to conduct online training & Webinar on Non-inferiority Trials: Practical Issues and Current Regulatory Perspectives.
Basic non-inferiority (NI) clinical study designs appear to provide a straightforward approach for evaluating whether a new drug or medical device is an appropriate substitute or replacement for a current standard treatment. In these studies the typical comparison is between a new drug and an active control with the goal of demonstrating that the new drug is “not inferior” to the standard treatment by “too large” a margin. Traditional approaches to demonstrating NI of a new drug amounted to a simple acceptance of the null hypothesis of no difference between that drug and an active control but are currently recognized as inadequate to support a claim of NI.
Course Objective:
This webinar will examine the philosophy and assumptions underlying NI trials by highlighting the differences among NI, equivalence, and superiority trials with regard to basic clinical study designs and appropriate hypothesis tests, power and sample size, and conceptual and statistical analysis differences. We will conclude with a review of current FDA guidance for NI clinical studies.
Course Outline:
Description and comparison of NI, equivalence, and superiority study objectives and designs.
Zeroing in on the specific clinical question to be asked.
Decision tree for choosing the appropriate design to answer the specific clinical question.
Why assay sensitivity matters and what you can do to maximize it.
How to determine the appropriate or acceptable “margin” of inferiority.
Appropriate hypothesis tests and statistical interpretation. (for nonstatisticians)
Target Audience:
FDA guidance Professionals who will benefit from this webinar include:
Clinical Research Professionals
Clinical Protocol Developers
Clinical Study Managers
Regulatory Managers
Clinical Studies Directors
Biostatisticians
Anyone who seeks to design appropriate clinical investigations for supporting anticipated labeling for a new drug or medical device.
Anyone who seeks to design appropriate clinical investigations that address the specific clinical development plan for a new drug or medical device while meeting the marketing goals of the company for that product.
*************************************************************************************
Complianz World offers Online Regulatory Compliance Training, Webinar & Seminar on Pharmaceuticals , Biotechnology , Medical Devices , FDA Compliance Training ,Clinical Research , Laboratory Compliance , Healthcare Compliance , Banking and Financial Services (BFSI) compliance training, Human Resources (HR) , OSHA , Trade and Logistics , GRC Regulations compliance training by expert speakers.
read full article